InventisBio
Dr. Zhang is leading the strategic planning and implementation of the clinical development plans at InventisBio. He has about 20 years of oncology clinical development experience covering small molecules and biologics at GSK, J&J, Sanofi, Schering-Plough, Merck and Daiichi Sankyo. He was involved in the design and management of several pivotal clinical trials leading to approval and marketing of 5 blockbuster drugs, including the melanoma clinical trial of the PD-1 antibody Keytruda®. Dr. Zhang got his M.D. degree from Fudan University School of Medicine (formerly Shanghai First Medical College) and his Ph.D. degree from Temple University.
This person is not in any offices
InventisBio
Yifang Biotechnology (Shanghai) Co., Ltd. is an entrepreneurial biomedical company established in 2013. It is committed to the research and development of new drugs in the fields of the tumor, tumor immunity, and metabolism. The company's product pipeline includes lung cancer, breast cancer, tumor immunity, and gout, etc. Small molecule drug candidates for targeted therapy in the field, and the company is also actively developing drugs for other tumor and immune tumor targets.